Biomarin Pharmaceutical (BMRN) Non-Current Assets (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Non-Current Assets data on file, last reported at $4.0 billion in Q1 2026.

• Quarterly Non-Current Assets rose 8.34% year-over-year to $4.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 billion (changed 0.0% YoY) and the FY2025 annual result came in at $3.6 billion, down 3.09% from the prior year.
• Non-Current Assets climbed to $4.0 billion in Q1 2026, from $3.6 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $4.0 billion in Q1 2026 to a low of $3.6 billion in Q3 2022.
• A 5-year average of $3.7 billion and a median of $3.7 billion in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2025 — Non-Current Assets slipped 5.36% — and 2026, when it gained 8.34%.
• Tracing BMRN's Non-Current Assets over 5 years: stood at $3.6 billion in 2022, then advanced by 7.23% to $3.9 billion in 2023, then retreated by 3.32% to $3.8 billion in 2024, then dropped by 3.09% to $3.6 billion in 2025, then climbed by 9.49% to $4.0 billion in 2026.
• The last three Non-Current Assets figures came in at $4.0 billion (Q1 2026), $3.6 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.